Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027

Cerevance announced closing a Series C supported by existing investors including Google Ventures. The financing extends runway through Phase 3 Parkinson’s disease trial readout and into mid-2027.